Pharma Mar has delivered a strong 84.7% gain over the past three years, yet the current share price of €66.60 puts a sharper spotlight on what investors are really paying for its earnings. With shorter term returns weaker this year, the question is whether that longer run still lines up with what the business is generating at the bottom line.
The stock's next move may depend on whether Pharma Mar's current earnings are strong enough to justify where the price now sits.
If you are weighing Pharma Mar's recent 3 year gain against its current earnings, it can help to compare it with 211 high quality undervalued stocks.
A P/E ratio works well for Pharma Mar because earnings are a key focus for investors in profitable biotechs. On this metric, the stock trades on a P/E of 16.9x, which is below the broader biotech industry average of about 23.9x and also under the peer group average of roughly 22.9x. That puts the current share price at a lower multiple of earnings than many similar companies in the sector.
The model driven fair multiple for Pharma Mar, which factors in its own growth profile, profitability and risk, sits higher than where the shares trade today. That gap points to a valuation that screens as undervalued on this earnings yardstick, while still leaving you to judge how sustainable those profits look across a full drug cycle. Explore the numbers behind Pharma Mar's P/E valuation.
Pharma Mar's valuation story now hinges on what has to be true about the future path of its earnings, and that is where Simply Wall St Narratives step in. These scenarios spell out the kind of growth, margin profile and risk balance that would need to unfold for the share price to look materially higher or lower than today. Each one connects its number to a specific view on how Pharma Mar's prospects might shift, giving you something concrete to revisit as fresh information emerges.
One of the top narratives on Pharma Mar: 47% undervalued
This is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.
"The numbers investors are paying for today imply a share price that does not fully reflect the potential impact of first-line Zepzelca approvals, Yondelis durability and the opportunity to in-license late-stage European oncology assets..."
Discover why this Narrative puts Pharma Mar at 47% undervalued.
Shareholders have picked over Pharma Mar's valuation, but the people steering the business and the way their incentives line up with your interests can be just as important to understand. See who runs Pharma Mar and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com